메뉴 건너뛰기




Volumn 86, Issue 2, 2011, Pages 117-123

Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma

(14)  Nagai, Hirokazu a   Ogura, Michinori b   Kusumoto, Shigeru c   Takahashi, Naoto d   Yamaguchi, Motoko e   Takayama, Nobuyuki f   Kinoshita, Tomohiro g   Motoji, Toshiko h   Ohyashiki, Kazuma i   Kosugi, Hiroshi j   Matsuda, Shin k   Ohnishi, Kazunori l   Omachi, Ken m   Hotta, Tomomitsu a  


Author keywords

Cladribine; Indolent B NHL; Rituximab; Salvage therapy

Indexed keywords

CLADRIBINE; RITUXIMAB;

EID: 78651432835     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01552.x     Document Type: Article
Times cited : (8)

References (38)
  • 1
    • 0037165261 scopus 로고    scopus 로고
    • CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
    • Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
    • (2002) N Engl J Med , vol.346 , pp. 235-42
    • Coiffier, B.1    Lepage, E.2    Briere, J.3
  • 2
    • 33646004738 scopus 로고    scopus 로고
    • CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
    • Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91.
    • (2006) Lancet Oncol , vol.7 , pp. 379-91
    • Pfreundschuh, M.1    Trumper, L.2    Osterborg, A.3
  • 3
    • 53749085410 scopus 로고    scopus 로고
    • Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma
    • Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579-86.
    • (2008) J Clin Oncol , vol.26 , pp. 4579-86
    • Marcus, R.1    Imrie, K.2    Solal-Celigny, P.3
  • 4
    • 28544435078 scopus 로고    scopus 로고
    • Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
    • Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32.
    • (2005) Blood , vol.106 , pp. 3725-32
    • Hiddemann, W.1    Kneba, M.2    Dreyling, M.3
  • 5
    • 0020612685 scopus 로고
    • Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes
    • Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983;62:737-43.
    • (1983) Blood , vol.62 , pp. 737-43
    • Carson, D.A.1    Wasson, D.B.2    Taetle, R.3    Yu, A.4
  • 8
    • 33751090057 scopus 로고    scopus 로고
    • 2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up
    • Gidron A, Tallman MS. 2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up. Leuk Lymphoma 2006;47:2301-7.
    • (2006) Leuk Lymphoma , vol.47 , pp. 2301-7
    • Gidron, A.1    Tallman, M.S.2
  • 9
    • 0031670669 scopus 로고    scopus 로고
    • Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients
    • Cheson BD, Sorensen JM, Vena DA, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol 1998;16:3007-15.
    • (1998) J Clin Oncol , vol.16 , pp. 3007-15
    • Cheson, B.D.1    Sorensen, J.M.2    Vena, D.A.3
  • 10
    • 0028010849 scopus 로고
    • Newer purine analogues for the treatment of hairy-cell leukemia
    • Saven A, Piro L. Newer purine analogues for the treatment of hairy-cell leukemia. N Engl J Med 1994;330:691-7.
    • (1994) N Engl J Med , vol.330 , pp. 691-7
    • Saven, A.1    Piro, L.2
  • 11
    • 67449103121 scopus 로고    scopus 로고
    • Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab
    • Tobinai K, Watanabe T, Tanimoto K, et al. Phase I/II and pharmacokinetic study of cladribine with 2-h infusion in Japanese patients with relapsed indolent B-cell lymphoma mostly pretreated with rituximab. Cancer Sci 2009;100:1344-50.
    • (2009) Cancer Sci , vol.100 , pp. 1344-50
    • Tobinai, K.1    Watanabe, T.2    Tanimoto, K.3
  • 13
    • 2942578934 scopus 로고    scopus 로고
    • Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone
    • Armitage JO, Tobinai K, Hoelzer D, Rummel MJ. Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone. Int J Hematol 2004;79:311-21.
    • (2004) Int J Hematol , vol.79 , pp. 311-21
    • Armitage, J.O.1    Tobinai, K.2    Hoelzer, D.3    Rummel, M.J.4
  • 15
    • 77952300539 scopus 로고    scopus 로고
    • Rituximab and subcutaneous 2-chloro-2′-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study
    • Laszlo D, Andreola G, Rigacci L, et al. Rituximab and subcutaneous 2-chloro-2′-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol 2010;28:2233-8.
    • (2010) J Clin Oncol , vol.28 , pp. 2233-8
    • Laszlo, D.1    Andreola, G.2    Rigacci, L.3
  • 16
    • 33750579912 scopus 로고    scopus 로고
    • Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial
    • Jager G, Neumeister P, Quehenberger F, Wohrer S, Linkesch W, Raderer M. Prolonged clinical remission in patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type treated with cladribine: 6 year follow-up of a phase II trial. Ann Oncol 2006;17:1722-3.
    • (2006) Ann Oncol , vol.17 , pp. 1722-3
    • Jager, G.1    Neumeister, P.2    Quehenberger, F.3    Wohrer, S.4    Linkesch, W.5    Raderer, M.6
  • 17
    • 48349121596 scopus 로고    scopus 로고
    • Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group
    • Kalinka-Warzocha E, Wajs J, Lech-Maranda E, Ceglarek B, Holowiecki J, Federowicz I, Walewski J, Czyz J, Robak T, Warzocha K. Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group. Cancer 2008;113:367-75.
    • (2008) Cancer , vol.113 , pp. 367-75
    • Kalinka-Warzocha, E.1    Wajs, J.2    Lech-Maranda, E.3    Ceglarek, B.4    Holowiecki, J.5    Federowicz, I.6    Walewski, J.7    Czyz, J.8    Robak, T.9    Warzocha, K.10
  • 18
    • 6944230907 scopus 로고    scopus 로고
    • Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study
    • Ogura M, Morishima Y, Kobayashi Y, et al. Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study. Int J Hematol 2004;80:267-77.
    • (2004) Int J Hematol , vol.80 , pp. 267-77
    • Ogura, M.1    Morishima, Y.2    Kobayashi, Y.3
  • 19
    • 34347383853 scopus 로고    scopus 로고
    • Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma
    • Robak T, Lech-Maranda E, Janus A, Blonski J, Wierzbowska A, Gora-Tybor J. Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma. Leuk Lymphoma 2007;48:1092-101.
    • (2007) Leuk Lymphoma , vol.48 , pp. 1092-101
    • Robak, T.1    Lech-Maranda, E.2    Janus, A.3    Blonski, J.4    Wierzbowska, A.5    Gora-Tybor, J.6
  • 20
    • 1842588045 scopus 로고    scopus 로고
    • Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies
    • Robak T, Smolewski P, Urbanska-Rys H, Gora-Tybor J, Blonski JZ, Kasznicki M. Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies. Leuk Lymphoma 2004;45:937-44.
    • (2004) Leuk Lymphoma , vol.45 , pp. 937-44
    • Robak, T.1    Smolewski, P.2    Urbanska-Rys, H.3    Gora-Tybor, J.4    Blonski, J.Z.5    Kasznicki, M.6
  • 21
    • 0031885544 scopus 로고    scopus 로고
    • Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma
    • Betticher DC, von Rohr A, Ratschiller D, et al. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma. J Clin Oncol 1998;16:850-8.
    • (1998) J Clin Oncol , vol.16 , pp. 850-8
    • Betticher, D.C.1    von Rohr, A.2    Ratschiller, D.3
  • 22
    • 0036024588 scopus 로고    scopus 로고
    • Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma
    • Rummel MJ, Chow KU, Karakas T, et al. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma. Eur J Cancer 2002;38:1739-46.
    • (2002) Eur J Cancer , vol.38 , pp. 1739-46
    • Rummel, M.J.1    Chow, K.U.2    Karakas, T.3
  • 23
    • 0030013103 scopus 로고    scopus 로고
    • Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma
    • Saven A, Lee T, Kosty M, Piro L. Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma. J Clin Oncol 1996;14:2139-44.
    • (1996) J Clin Oncol , vol.14 , pp. 2139-44
    • Saven, A.1    Lee, T.2    Kosty, M.3    Piro, L.4
  • 24
    • 77951628255 scopus 로고    scopus 로고
    • Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study)
    • Robak T, Jamroziak K, Gora-Tybor J, et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). J Clin Oncol 2010;28:1863-9.
    • (2010) J Clin Oncol , vol.28 , pp. 1863-9
    • Robak, T.1    Jamroziak, K.2    Gora-Tybor, J.3
  • 25
    • 20044368632 scopus 로고    scopus 로고
    • Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma
    • Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol 2005;23:694-704.
    • (2005) J Clin Oncol , vol.23 , pp. 694-704
    • Czuczman, M.S.1    Koryzna, A.2    Mohr, A.3
  • 26
    • 4344660758 scopus 로고    scopus 로고
    • Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma
    • Zinzani PL, Pulsoni A, Perrotti A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004;22:2654-61.
    • (2004) J Clin Oncol , vol.22 , pp. 2654-61
    • Zinzani, P.L.1    Pulsoni, A.2    Perrotti, A.3
  • 27
    • 8744274334 scopus 로고    scopus 로고
    • The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
    • Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064-71.
    • (2004) Blood , vol.104 , pp. 3064-71
    • Forstpointner, R.1    Dreyling, M.2    Repp, R.3
  • 28
    • 70349591632 scopus 로고    scopus 로고
    • Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma
    • Tobinai K, Ishizawa K, Ogura M, et al. Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma. Cancer Sci 2009;100:1951-6.
    • (2009) Cancer Sci , vol.100 , pp. 1951-6
    • Tobinai, K.1    Ishizawa, K.2    Ogura, M.3
  • 29
    • 0003477486 scopus 로고    scopus 로고
    • World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues
    • Jaffe ES, Harris NL, Stein H, Vardiman JW, eds., 3rd edn. Geneva, Switzerland: World Health Organization,
    • Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues, 3rd edn. Geneva, Switzerland: World Health Organization, 2001.
    • (2001)
  • 31
    • 0042449063 scopus 로고    scopus 로고
    • Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group
    • Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-53.
    • (1999) J Clin Oncol , vol.17 , pp. 1244-53
    • Cheson, B.D.1    Horning, S.J.2    Coiffier, B.3
  • 32
    • 10744228140 scopus 로고    scopus 로고
    • CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment
    • Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81.
    • (2003) Semin Radiat Oncol , vol.13 , pp. 176-81
    • Trotti, A.1    Colevas, A.D.2    Setser, A.3
  • 33
    • 4444326818 scopus 로고    scopus 로고
    • Follicular lymphoma international prognostic index
    • Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258-65.
    • (2004) Blood , vol.104 , pp. 1258-65
    • Solal-Celigny, P.1    Roy, P.2    Colombat, P.3
  • 34
    • 0036682214 scopus 로고    scopus 로고
    • Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma
    • Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262-9.
    • (2002) J Clin Oncol , vol.20 , pp. 3262-9
    • Witzig, T.E.1    Flinn, I.W.2    Gordon, L.I.3
  • 35
    • 33644845422 scopus 로고    scopus 로고
    • Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma
    • Tobinai K, Watanabe T, Ogura M, et al. Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma. J Clin Oncol 2006;24:174-80.
    • (2006) J Clin Oncol , vol.24 , pp. 174-80
    • Tobinai, K.1    Watanabe, T.2    Ogura, M.3
  • 36
    • 72149085331 scopus 로고    scopus 로고
    • Cladribine (CdA) gives longer response duration than fludarabine (F) and high-dose intermittent clorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukemia (CLL): first results from the International Randomized Phase III Trial
    • (suppl) abstr 630.
    • Karlsson KA, Strömberg M, Jönsson V, Mulligan SP, Liliemark J, Juliussonet G. Cladribine (CdA) gives longer response duration than fludarabine (F) and high-dose intermittent clorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukemia (CLL): first results from the International Randomized Phase III Trial. Blood 2007;110:194a; (suppl) abstr 630.
    • (2007) Blood , vol.110
    • Karlsson, K.A.1    Strömberg, M.2    Jönsson, V.3    Mulligan, S.P.4    Liliemark, J.5    Juliussonet, G.6
  • 37
    • 0028918514 scopus 로고
    • Cellular pharmacokinetics of 2-chloro-2′-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients
    • Liliemark J, Juliusson G. Cellular pharmacokinetics of 2-chloro-2′-deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Cancer Res 1995;4:385-90.
    • (1995) Clin Cancer Res , vol.4 , pp. 385-90
    • Liliemark, J.1    Juliusson, G.2
  • 38
    • 18544404548 scopus 로고    scopus 로고
    • Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4 + lymphocytopenia after treatment
    • Bastie JN, Cazals-Hatem D, Daniel MT, et al. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4 + lymphocytopenia after treatment. Leuk Lymphoma 1999;35:555-65.
    • (1999) Leuk Lymphoma , vol.35 , pp. 555-65
    • Bastie, J.N.1    Cazals-Hatem, D.2    Daniel, M.T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.